Skip to main content
. 2022 Dec 5;14(12):2721. doi: 10.3390/pharmaceutics14122721

Figure 9.

Figure 9

Adverse events associated with FDA-approved biosimilars used in treatment of A. liver; B. cardiovascular; C. Lung; D. Uterine and cervical; E. Gastrointestinal; F. Brain; G. Kidneys; and H. Circulatory System [42,52,58,59,60,66,67,69,73,74,75,76,77,79].